As a common cardiovascular disease, coronary heart disease (CHD) continues to be the leading cause of mortality as well as morbidity. The prevention and treatment of coronary heart disease (CHD) has become an important topic in the whole society. It is of great clinical significance to associate angiogenesis with the pathogenesis of coronary atherosclerosis, acute myocardial infarction (AMI), and cardiogenic shock after AMI. Therapeutic angiogenesis may provide new treatment options for patients with coronary heart disease. Angiopoietin (Angiopoietins, Angs)-Tie pathway is an important signal transduction pathway involved in angiogenesis, including Ang1, Ang2, Ang3, Ang4 and its receptor Tie1, Tie2. At present, there are more studies on Ang1, Ang2 and Tie2, in which Ang1-Tie2 mainly maintains vascular system stability, and Ang2-Tie2 is closely related to vascular remodeling. Both plaque growth and instability in atherosclerosis involve neovascularization. Angs is a key factor from the initial stage of plaque formation to the occurrence of acute cardiovascular events. Angs also plays a key role in the pathogenesis of unstable angina pectoris cardiogenic, AMI, and cardiogenic shock after AMI. Angs can become a new indicator of the occurrence and development of these diseases. In treatment, Angs-Tie pathway is a potential therapeutic target for early prevention of coronary atherosclerosis, improvement of cardiac perfusion and function after myocardial infarction, and promotion of collateral circulation. This article reviews the mechanism and significance of Angs-Tie pathway in coronary heart disease.